Schultz et al. [26] found that high IL-6 in pancreatic cancer patients was associated with short OS, and in multivariate analyses, the HR was 1.71 (95% CI 1.33–2.20) for high serum IL-6 and 1.54 (95% CI 1.06–2.24) for high serum CA 19.9 in patients with locally advanced or metastatic pancreatic cancer. This evidence concerns the gene IL6 and pancreatic neoplasm.